Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta
Rattachement africain : gb, de, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Reversible lymphocyte count reductions have occurred following daclizumab beta treatment for relapsing–remitting multiple sclerosis. Objective: To analyse total and differential lymphocyte levels and relationship with infection status. Methods: In DECIDE, blood samples were collected at 12-week intervals from daclizumab beta- ( n = 919) or intramuscular interferon beta-1a–treated ( n = 922) patients. Infections/serious infections were assessed proximate to grade 2/3 lymphopenia or low CD4 + /CD8 + T-cell counts. Total safety population (TSP) data were additionally analysed from the entire clinical development programme ( n = 2236). Results: Over 96 weeks in DECIDE, mean absolute lymphocyte count (ALC), CD4 + and CD8 + T-cell counts decreased <10% (7.1% vs 1.6%, 9.7% vs 2.0%, 9.3% vs 5.9%: daclizumab beta vs interferon beta-1a, respectively); shifts to ALC below lower limit of normal occurred in 13% versus 15%, respectively. Grade 3 lymphopenia was uncommon (TSP: <1%) and transient. Lymphocyte changes generally occurred within 24 weeks after treatment initiation and were reversible within 12 weeks of discontinuation. In DECIDE, mean CD4 + /CD8 + T-cell counts were similar regardless of infection status. TSP data were consistent with DECIDE. Conclusion: When observed, ALC and CD4 + /CD8 + T-cell count decreases in daclizumab beta–treated patients were generally mild-to-modest, reversible upon treatment discontinuation and not associated with increased risk of infections, including opportunistic infections.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta
- Date Crossref
- 15/09/2017
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Queen Mary University of London pays non établi dans la noticeUniversité ou école supérieure
-
Blizard Institute pays non établi dans la noticeUniversité ou école supérieure
-
University of Münster Department of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
Barts Health NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Biogen (United States) pays non établi dans la noticeEntreprise
-
AbbVie (United States) pays non établi dans la noticeEntreprise
-
Barts and the London School of Medicine and Dentistry Blizard Institute pays non établi dans la noticeUniversité ou école supérieure
-
Barts and the London NHS Trust pays non établi dans la noticeInstitution
-
Inc. AbbVie pays non établi dans la noticeEntreprise
Queen Mary University of London, Blizard Institute et Department of Neurology — University of Münster, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.